Acrux Limited (ASX:ACR) Announces Share Purchase Plan and Product Launch
Acrux Limited (ASX:ACR) announces a successful FDA product approval and launches a Share Purchase Plan.
Category: Healthcare
Race Oncology Ltd (ASX:RAC) Receives $5.25m R&D Tax Refund
Race Oncology Ltd announces a $5.25 million R&D tax refund to advance clinical development efforts for RC220.
Vection Technologies Ltd (ASX:VR1) Announces Algho AI Trials
Vection Technologies Ltd (ASX:VR1) announces the launch of full-scale Algho AI trials at Massachusetts General Hospital, showcasing significant growth potential.
dorsaVi Ltd (ASX:DVL) Partners with Secret Network for Blockchain Innovation
dorsaVi Ltd partners with Secret Network to integrate blockchain technology, enhancing privacy and security for wearable movement data.
NOVONIX Limited (ASX: NVX) Secures Conditional US$754 Million Loan Commitment
NOVONIX Limited announces a conditional commitment for a US$754 million loan to support its new graphite manufacturing facility in Tennessee.
Immutep Limited (ASX: IMM) Reports Initial Safety Data for IMP761
Immutep Limited announces positive initial safety data for its LAG-3 agonist IMP761 from a Phase I human trial.
Pantoro Limited (ASX:PNR) Finalises Mining Agreement with Ngadju
Pantoro Limited finalises a Mining Agreement with Ngadju Native Title Aboriginal Corporation for its Norseman Gold Project.
PainChek Limited (ASX:PCK) Completes AUD $5.1 Million Entitlement Offer
PainChek Limited completes a successful Entitlement Offer, raising AUD $5.1 million for market expansion and product development.
Patrys Limited (ASX:PAB) Receives R&D Tax Incentive Refund
Patrys Limited (ASX:PAB) secures $1.285 million in R&D Tax Incentive funding to advance its therapeutic antibody development initiatives.
Chimeric Therapeutics (ASX:CHM) Advances Phase 1B AML Trial
Chimeric Therapeutics (ASX:CHM) advances its ADVENT-AML Phase 1B trial for newly diagnosed AML patients.